CRISPR-Cas9 Mediated Gene Correction of CFTR Mutations in Cystic Fibrosis: Evaluating Efficacy, Safety, and Long-Term Outcomes in Patient-Derived Lung Organoids

Melda DÖLARSLAN

DOI: https://doi.org/10.70470/shifaa/2023/005

2023-05-19

Abstract:Cystic fibrosis (CF) is a genetic disorder caused by mutations in the *CFTR* gene, leading to severe respiratory and digestive problems. Current therapies including AAV gene therapy, small molecule modifiers, and RNA-based therapies only partially restore *CFTR* function, leaving a need for more effective therapies The aim of this review is to address CRISPR-1. Cas9-mediated genetic correction in patient derived lung organoids Efficacy, safety and long-term outcomes are evaluated as a novel strategy for CF therapy. Our goal was to achieve high gene editing efficiency, restore *CFTR* function to near normal levels, and evaluate the safety of this approach by monitoring off-target effects CRISPR-Cas9 achieved 75% average gene editing efficiency, with recovery of *CFTR* function up to 85%, AAV gene therapy (35% efficiency, 50). % Functional restoration), small molecule modulators (60% functional restoration), and... RNA-based therapy (57% functional restoration). Off-target effects were small, observed at 0.5%, confirming the accuracy of CRISPR-Cas9 in correcting *CFTR* mutations. The use of patient-derived lung organoids proved important for modeling the ailment and trying out healing interventions, providing excessive personalization ability and the cap potential to reveal long-time period stability. The look at concludes that CRISPR-Cas9, while carried out to patient-derived lung organoids, represents a promising development withinside the remedy of Cystic Fibrosis, providing advanced efficacy and personalization as compared to present methods. However, the excessive fee and moral concerns related to CRISPR-Cas9 necessitate similarly studies to optimize its utility and make sure its protection in medical settings.